Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Ahmed Abdulrahman Al Mathehaji: LMWH Is Preferred Despite Elevated INR in Decompensated Cirrhosis
Ahmed Abdulrahman Al Mathehaji/X
Aug 20, 2026, 18:01

Ahmed Abdulrahman Al Mathehaji: LMWH Is Preferred Despite Elevated INR in Decompensated Cirrhosis

Ahmed Abdulrahman Al Mathehaji, Internal Medicine Specialist and Gastroenterology, Hepatology, Endoscopy Fellow, shared a post on X:

“Low molecular weight heparin (LMWH) is the preferred anticoagulant for treating acute deep vein thrombosis in patients with decompensated cirrhosis, regardless of the elevated INR.

The elevated INR should not be considered an absolute contraindication to anticoagulation, as it reflects impaired hepatic synthetic function rather than true anticoagulation status in cirrhosis.

Direct oral anticoagulants (DOACs) are contraindicated in decompensated cirrhosis, particularly in Child-Pugh class C patients and critically ill individuals, due to hepatic metabolism and unpredictable drug levels.

While DOACs may be considered in compensated cirrhosis (Child-Pugh class A or B), they should be avoided in decompensated disease.

LMWH has demonstrated superior outcomes in cirrhotic patients with venous thromboembolism, achieving higher recanalization rates (71% vs 42% without treatment) and lower variceal bleeding risk compared to no anticoagulation. Meta-analyses confirm that LMWH produces more complete recanalization than warfarin and reduces all-cause mortality.

Warfarin may be considered as an alternative if LMWH is contraindicated, though INR monitoring is problematic in cirrhosis due to baseline coagulopathy and uncertain target ranges. Historical studies have used INR targets of 2-3, but this approach requires careful individualization.

The decision to anticoagulate should be individualized based on extent of thrombosis, bleeding risk, platelet count (generally safe if more than 50,000/μL), and fall risk rather than INR alone.

Active bleeding would be a contraindication, but thrombocytopenia and prolonged INR should not automatically preclude treatment.”

Stay updated with Hemostasis Today.

Acute Deep Vein Thrombosis Ahmed Abdulrahman Al Mathehaji Anticoagulation Blood Decompensated Cirrhosis Direct Oral Anticoagulants DOACs DVT Health Hematology Hemostasis Hemostasis News Hemostasis Today INR LMWH Low-Molecular-Weight Heparin Medicine venous thromboembolism VTE Warfarin
NewsFeed